News | June 16, 2023
PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)
Subscribe To Our Newsletter & Stay Updated
